0.9387

1.54% 0.0142

Pre-market: .92 -0.0187 -1.99%

Akebia Therapeutics Inc (AKBA)

Overview News Price History Option Chain Financials Discussions Forecast

Akebia Therapeutics Inc stock is traded at $0.9387, with a volume of 5.53M. It is up +1.54% in the last 24 hours and down -11.44% over the past month. Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Previous Close:

$0.9245

Open:

$0.9318

24h Volume:

5.53M

Relative Volume:

1.42

Market Cap:

$251.81M

Revenue:

$232.40M

Net Income/Loss:

$-20.51M

P/E Ratio:

-12.18

EPS:

-0.0771

Net Cash Flow:

$60.04M

1W Performance:

+0.33%

1M Performance:

-11.44%

6M Performance:

-41.70%

1Y Performance:

-73.63%

1-Day Range:

$0.90

$0.9423

1-Week Range:

$0.8227

$0.9598

52-Week Range:

$0.8227

$4.0787

Akebia Therapeutics Inc Stock (AKBA) Company Profile

Name

Akebia Therapeutics Inc

Sector

Healthcare (1104)

Industry

Drug Manufacturers - Specialty & Generic (88)

Phone

617-871-2098

Address

245 FIRST STREET, CAMBRIDGE, MA

Employee

194

Twitter

@akebiatx

Next Earnings Date

2026-08-06

Latest SEC Filings

AKBA's Discussions on Twitter

Compare AKBA vs TAK, HLN, TEVA, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AKBA Akebia Therapeutics Inc	0.9387	251.81M	232.40M	-20.51M	60.04M	-0.0771
TAK Takeda Pharmaceutical Co Adr	15.77	49.83B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.07	40.04B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	33.69	39.23B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	79.95	33.52B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	549.57	23.33B	3.17B	1.29B	1.01B	27.09

Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-04-25	Resumed	H.C. Wainwright	Buy
Apr-28-25	Initiated	Leerink Partners	Outperform
Apr-01-25	Initiated	Jefferies	Buy
Nov-29-23	Resumed	BTIG Research	Buy
Aug-28-23	Upgrade	H.C. Wainwright	Neutral → Buy
May-31-23	Upgrade	Piper Sandler	Neutral → Overweight
Mar-31-22	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-31-22	Downgrade	Mizuho	Buy → Neutral
Mar-31-22	Downgrade	Needham	Buy → Hold
Mar-31-22	Downgrade	Piper Sandler	Overweight → Neutral
Mar-08-21	Initiated	Cantor Fitzgerald	Overweight
Jan-29-21	Downgrade	JP Morgan	Neutral → Underweight
Nov-14-19	Reiterated	Needham	Buy
Aug-06-19	Reiterated	H.C. Wainwright	Buy
Jul-11-19	Reiterated	H.C. Wainwright	Buy
May-02-19	Initiated	JP Morgan	Overweight
Mar-20-19	Initiated	Citigroup	Neutral
Sep-07-18	Resumed	Morgan Stanley	Equal-Weight
Aug-10-18	Reiterated	Needham	Buy
Jun-06-18	Reiterated	H.C. Wainwright	Buy
Dec-19-17	Initiated	Piper Jaffray	Overweight
Dec-07-17	Initiated	BTIG Research	Buy
Sep-15-17	Initiated	RBC Capital Mkts	Sector Perform
Jul-10-17	Reiterated	H.C. Wainwright	Buy
Apr-27-17	Reiterated	H.C. Wainwright	Buy
Apr-27-17	Reiterated	Needham	Buy
Dec-27-16	Reiterated	H.C. Wainwright	Buy
Dec-20-16	Reiterated	JMP Securities	Mkt Outperform
Nov-15-16	Initiated	Aegis Capital	Buy
Sep-29-16	Initiated	Brean Capital	Buy
Mar-16-16	Reiterated	Needham	Buy
Jan-21-16	Initiated	Credit Suisse	Neutral

View All

Akebia Therapeutics Inc Stock (AKBA) Latest News

Jun 14, 2026

AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction - Stocktwits

Jun 14, 2026

Jun 10, 2026

Akebia Therapeutics sees Vafseo uptake rising as access and pipeline milestones near - MSN

Jun 10, 2026

Akebia Strengthens Patent Portfolio with New Grant for Vafseo (A - GuruFocus

Jun 10, 2026

Akebia receives new patent, extension eligibility for Vafseo - Investing.com

Jun 10, 2026

Akebia receives new patent, extension eligibility for Vafseo By Investing.com - Investing.com South Africa

Jun 10, 2026

Akebia Therapeutics Secures New Patent Covering Dosing Regimen for Chronic Kidney Disease - marketscreener.com

Jun 10, 2026

Akebia Therapeutics Announces New Patent and Patent Extension Eligibility for Vafseo® (vadadustat) Strengthening Intellectual Property Portfolio - Quiver Quantitative

Jun 10, 2026

Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio - GlobeNewswire

Jun 10, 2026

Jun 06, 2026

Akebia’s Vafseo gains traction as $106B pharma M&A reshapes sector - MSN

Jun 06, 2026

Jun 04, 2026

Akebia Therapeutics Sees Vafseo Uptake Rising as Access and Pipeline Milestones Near - MarketBeat

Jun 04, 2026

AKBA: Vafseo growth accelerates, pipeline advances, and broad access expected post-2026 - TradingView

Jun 04, 2026

Jun 02, 2026

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jun 02, 2026

May 29, 2026

AKBA Stock Price, Quote & Chart | AKEBIA THERAPEUTICS INC (NASDAQ:AKBA) - ChartMill

May 29, 2026

May 28, 2026

Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference - The Manila Times

May 28, 2026

May 27, 2026

AKBA Q1 2026 Earnings: EPS Misses Estimates Amid Operational DevelopmentsEarnings Cycle Report - thelegaladvocate.com

May 27, 2026

AKBA Q1 2026 Earnings: EPS Misses Estimates as Stock Holds SteadyEarnings Surprise Stocks - thelegaladvocate.com

May 27, 2026

May 26, 2026

Akebia Therapeutics (AKBA) Edges Higher at $1.04 – Key Levels in FocusFair Value Gap - thelegaladvocate.com

May 26, 2026

Promising Penny Stocks To Consider In May 2026 - Yahoo Finance

May 26, 2026

May 24, 2026